KaloBios Pharmaceuticals, Inc.

- -

- -

- -

- -

- -

- -

- -

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase I clinical trial in patients with chronic myelomonocytic leukemia; and ifabotuzumab that has completed Phase I/II clinical trial in multiple hematologic malignancies, as well as evaluating further studies of ifabotuzumab in rare solid tumors, such as glioblastoma, other brain cancers in children, and rare hematologic cancer indications. In addition, it has an additional drug candidate, KB001-A, a recombinant, PEGylated, anti-Pseudomonas PcrV high-affinity Fab’ antibody. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is based in Brisbane, California.